Abstract
One in 20 deaths were from Chronic Obstructive Pulmonary Disease (COPD) in 2015. The TONADO 1 and 2 studies demonstrated that Tiotropium-Olodaterol significantly improved lung function and symptoms compared to monocomponents.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
